Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXOZ NASDAQ:NMRA NASDAQ:RCKT NASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXOZeXoZymes$10.07-0.3%$11.23$8.50▼$23.99$84.31MN/A5,751 shs1,060 shsNMRANeumora Therapeutics$1.56-20.4%$1.15$0.61▼$17.19$252.33M2.872.20 million shs2.11 million shsRCKTRocket Pharmaceuticals$2.99-2.0%$2.97$2.19▼$22.01$319.29M0.653.10 million shs1.89 million shsRNACCartesian Therapeutics$12.33-3.7%$11.27$8.46▼$26.50$320.01M0.4371,639 shs77,855 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXOZeXoZymes0.00%+0.90%+1.61%-7.53%+1,006,999,900.00%NMRANeumora Therapeutics0.00%-33.62%+92.36%+100.98%-87.87%RCKTRocket Pharmaceuticals0.00%-4.78%+3.25%-62.67%-87.64%RNACCartesian Therapeutics0.00%-7.50%+10.34%-2.91%-24.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXOZeXoZymesN/AN/AN/AN/AN/AN/AN/AN/ANMRANeumora Therapeutics2.4067 of 5 stars3.13.00.00.00.62.51.3RCKTRocket Pharmaceuticals4.8363 of 5 stars4.24.00.04.71.74.21.3RNACCartesian Therapeutics1.4027 of 5 stars3.40.00.00.00.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXOZeXoZymes 0.00N/AN/AN/ANMRANeumora Therapeutics 2.22Hold$7.14357.88% UpsideRCKTRocket Pharmaceuticals 2.35Hold$17.87497.55% UpsideRNACCartesian Therapeutics 2.83Moderate Buy$40.00224.41% UpsideCurrent Analyst Ratings BreakdownLatest EXOZ, NMRA, RCKT, and RNAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/25/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.007/25/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$9.00 ➝ $4.007/24/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $12.007/24/2025RCKTRocket PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold7/16/2025NMRANeumora TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.007/9/2025RNACCartesian TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.006/17/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.006/3/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $11.005/30/2025RCKTRocket PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ In-Line$5.005/28/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025RCKTRocket PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXOZeXoZymes$70K1,204.08N/AN/A$1.25 per share8.06NMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ARNACCartesian Therapeutics$38.91M8.22N/AN/A($0.27) per share-45.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXOZeXoZymes-$5.86MN/A0.00∞N/AN/AN/AN/AN/ANMRANeumora Therapeutics-$243.79M-$1.61N/AN/AN/AN/A-84.79%-77.57%8/6/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)RNACCartesian Therapeutics-$77.42M-$52.83N/AN/AN/AN/AN/A-7.01%8/6/2025 (Estimated)Latest EXOZ, NMRA, RCKT, and RNAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025N/ARNACCartesian Therapeutics-$0.77N/AN/AN/A$0.77 millionN/A8/6/2025Q2 2025NMRANeumora Therapeutics-$0.38N/AN/AN/AN/AN/A8/4/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57N/AN/AN/A$4.36 millionN/A5/13/2025Q1 2025RCKTRocket Pharmaceuticals-$0.58-$0.56+$0.02N/AN/AN/A5/12/2025Q1 2025EXOZeXoZymesN/A-$0.22N/A-$0.22N/AN/A5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/8/2025Q1 2025RNACCartesian Therapeutics-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 million5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59-$0.56+$0.03-$0.56$0.80 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXOZeXoZymesN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXOZeXoZymesN/A6.526.52NMRANeumora TherapeuticsN/A8.988.98RCKTRocket Pharmaceuticals0.059.199.19RNACCartesian TherapeuticsN/A12.3412.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXOZeXoZymesN/ANMRANeumora Therapeutics47.65%RCKTRocket Pharmaceuticals98.39%RNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipEXOZeXoZymes72.41%NMRANeumora Therapeutics26.80%RCKTRocket Pharmaceuticals24.76%RNACCartesian Therapeutics60.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXOZeXoZymes298.37 million2.31 millionN/ANMRANeumora Therapeutics108161.75 million118.40 millionOptionableRCKTRocket Pharmaceuticals240106.79 million80.35 millionOptionableRNACCartesian Therapeutics6425.95 million10.30 millionOptionableEXOZ, NMRA, RCKT, and RNAC HeadlinesRecent News About These CompaniesCartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?July 24, 2025 | zacks.comBrokers Set Expectations for RNAC Q2 EarningsJuly 11, 2025 | marketbeat.comWedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform RecommendationJuly 9, 2025 | msn.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 9, 2025 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Earns Outperform Rating from Analysts at WedbushJuly 9, 2025 | marketbeat.comWe're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateJune 21, 2025 | finance.yahoo.comCartesian Therapeutics holds annual stockholders meetingJune 17, 2025 | investing.comCartesian Therapeutics Announces New Employment Inducement GrantsJune 3, 2025 | globenewswire.comBTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)June 2, 2025 | theglobeandmail.comCartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisMay 30, 2025 | globenewswire.comCartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 13, 2025 | manilatimes.netMAnalysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)May 11, 2025 | theglobeandmail.comCartesian Therapeutics (RNAC) Gets a Buy from Mizuho SecuritiesMay 11, 2025 | theglobeandmail.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 11, 2025 | finance.yahoo.comCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comWhy Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside PotentialMay 5, 2025 | insidermonkey.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 2, 2025 | globenewswire.comCartesian Therapeutics management to meet with BTIGApril 26, 2025 | markets.businessinsider.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%April 22, 2025 | aaii.comAWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 6.62%April 15, 2025 | aaii.comAWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 21.84%April 15, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXOZ, NMRA, RCKT, and RNAC Company DescriptionseXoZymes NASDAQ:EXOZ$10.07 -0.03 (-0.30%) As of 08/1/2025 01:58 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Neumora Therapeutics NASDAQ:NMRA$1.56 -0.40 (-20.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.64 +0.09 (+5.45%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Rocket Pharmaceuticals NASDAQ:RCKT$2.99 -0.06 (-1.97%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.02 +0.03 (+0.97%) As of 08/1/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Cartesian Therapeutics NASDAQ:RNAC$12.33 -0.48 (-3.75%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.32 -0.01 (-0.04%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
